Qinping Liao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qinping Liao has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
Rui Chen
School of Clinical Medicine, Tsinghua University, Beijing, CHINA
9 shared publicationsJian Zhao
Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China
7 shared publicationsRuifang An
Department of Gynecology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, People’s Republic of China
7 shared publicationsLei Zhang
Department of Obstetrics and Gynecology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University
6 shared publicationsYing Wang
Department of Obstetrics and Gynecology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University
6 shared publicationsJia Wen
Department of Obstetrics and Gynecology, Beijing TsingHua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China
5 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-12
Efficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized by Candida Species and Previous Genital Tract Infection: A Post Hoc Analysis of a Phase 3 Trial
Purpose: Oteseconazole, a novel selective fungal CYP51 inhibitor, demonstrated superior efficacy over fluconazole for severe vulvovaginal candidiasis (SVVC) in a phase 3 trial. However, whether the efficacy and safety of oteseconazole on SVVC varies by Candida species or previous genital tract infection remains unknown. Patients and Methods: In this exploratory post hoc analysis of a phase 3 trial (NCT04956419), data were analyzed from patients with SVVC receiving oteseconazole (600 mg on day 1 and 450 mg on day 2) or fluconazole (150 mg on days 1 and 4). The primary outcome was therapeutic cure rate at day 28, assessed in subgroups categorized by Candida species (Candida albicans vs. non-Candida albicans) and previous genital tract infection (yes vs. no). Results: Of 319 patients categorized by Candida species or previous genital tract infection (oteseconazole, n = 160; fluconazole, n = 159), 249 were in the Candida albicans subgroup and 70 in the non-Candida albicans subgroup. Regarding previous infection, 107 had previous genital tract infection, while 212 had none. At day 28, the therapeutic cure rates were higher with oteseconazole than with fluconazole across subgroups categorized by Candida species (Candida albicans: 76.56% vs 56.20%, propensity score [PS]-weighted odds ratio [OR] 2.59 [95% CI 1.76, 3.81]; non-Candida albicans: 28.13% vs 13.16%, PS-weighted OR 2.78 [95% CI 1.17, 6.64]) and previous genital tract infection (yes: 61.70% vs 45.00%, PS-weighted OR 2.03 [95% CI 1.18, 3.51]); no: 69.03% vs 46.46%, PS-weighted OR 2.59 [95% CI 1.74, 3.85]). Additionally, the incidence of treatment-emergent adverse events was comparable between oteseconazole and fluconazole across all subgroups. Conclusion: Oteseconazole may offer benefits and is generally well tolerated in patients with SVVC, irrespective of Candida species and previous genital tract infection. However, given the exploratory post hoc nature and the relatively small subgroup sample size, these findings warrant further validation in larger studies.
- 1 June 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-12
Open AccessEfficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized by Candida Species and Previous Genital Tract Infection: A Post Hoc Analysis of a Phase 3 Trial
Purpose: Oteseconazole, a novel selective fungal CYP51 inhibitor, demonstrated superior efficacy over fluconazole for severe vulvovaginal candidiasis (SVVC) in a phase 3 trial. However, whether the efficacy and safety of oteseconazole on SVVC varies by Candida species or previous genital tract infection remains unknown. Patients and Methods: In this exploratory post hoc analysis of a phase 3 trial (NCT04956419), data were analyzed from patients with SVVC receiving oteseconazole (600 mg on day 1 and 450 mg on day 2) or fluconazole (150 mg on days 1 and 4). The primary outcome was therapeutic cure rate at day 28, assessed in subgroups categorized by Candida species (Candida albicans vs. non-Candida albicans) and previous genital tract infection (yes vs. no). Results: Of 319 patients categorized by Candida species or previous genital tract infection (oteseconazole, n = 160; fluconazole, n = 159), 249 were in the Candida albicans subgroup and 70 in the non-Candida albicans subgroup. Regarding previous infection, 107 had previous genital tract infection, while 212 had none. At day 28, the therapeutic cure rates were higher with oteseconazole than with fluconazole across subgroups categorized by Candida species (Candida albicans: 76.56% vs 56.20%, propensity score [PS]-weighted odds ratio [OR] 2.59 [95% CI 1.76, 3.81]; non-Candida albicans: 28.13% vs 13.16%, PS-weighted OR 2.78 [95% CI 1.17, 6.64]) and previous genital tract infection (yes: 61.70% vs 45.00%, PS-weighted OR 2.03 [95% CI 1.18, 3.51]); no: 69.03% vs 46.46%, PS-weighted OR 2.59 [95% CI 1.74, 3.85]). Additionally, the incidence of treatment-emergent adverse events was comparable between oteseconazole and fluconazole across all subgroups. Conclusion: Oteseconazole may offer benefits and is generally well tolerated in patients with SVVC, irrespective of Candida species and previous genital tract infection. However, given the exploratory post hoc nature and the relatively small subgroup sample size, these findings warrant further validation in larger studies.
- Open Access
- 7 January 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (1) , e0169124
AI-assisted diagnosis of vulvovaginal candidiasis using cascaded neural networks
Vulvovaginal candidiasis (VVC) is a prevalent fungal ailment affecting women globally. Timely and accurate diagnosis is crucial. Traditional methods, relying on clinical evaluation and manual microscopic examination, have limitations. Artificial intelligence (AI) offers potential improvements in diagnostic accuracy and efficiency by objectively analyzing microscopic images of lower genital tract infections in women. A cascaded model was developed using 100,387 microscope images and 1,761 slides to diagnose VVC at slide level. The model’s diagnostic accuracy was compared with experts’. Five hundred thirteen slides were used to evaluate whether the experts’ diagnostic skills could be improved using the model as an AI-assisted tool. The consistency between experts’ interpretations of microscopic digital images and microscopic examination under eyepiece was assessed to determine whether the collected images adequately represented the slides. The model obtained AUC = 0.9447, 0.9711, and 0.9793 for slide-level diagnosing yeast hyphae, budding yeast, and yeast. Compared with the average performance of experts, the Youden indexes of our model’s best points were improved by 0.0069, 0.0772, 0.0579, and 0.0907 for yeast hyphae, budding yeast, yeast, and VVC. The average accuracy of the experts was improved by 5.98%, 5.20%, 4.82%, and 8.19% using our model as an AI-assisted tool. The consistency rates and Cohen’s kappa coefficients between experts’ interpretations of microscopic digital images and microscopic examination under eyepiece exceeded 93% and 0.83 for the three different morphologic states of yeast. Our model exhibits superior diagnostic accuracy for VVC compared to experts. Experts can significantly improve their own diagnostic accuracies by using our model as an AI-assisted tool. The microscope images collected from each slide effectively represent the slide. IMPORTANCE: A cascaded deep neural network model was developed for slide-level diagnosis of vulvovaginal candidiasis (VVC), demonstrating superior diagnostic accuracy compared to experts. Experts significantly enhanced their diagnostic accuracies by utilizing our model as an AI-assisted tool. Therefore, this model holds potential for clinical application to aid in the diagnosis of VVC.
- 7 January 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (1) , e0169124
Open AccessAI-assisted diagnosis of vulvovaginal candidiasis using cascaded neural networks
Vulvovaginal candidiasis (VVC) is a prevalent fungal ailment affecting women globally. Timely and accurate diagnosis is crucial. Traditional methods, relying on clinical evaluation and manual microscopic examination, have limitations. Artificial intelligence (AI) offers potential improvements in diagnostic accuracy and efficiency by objectively analyzing microscopic images of lower genital tract infections in women. A cascaded model was developed using 100,387 microscope images and 1,761 slides to diagnose VVC at slide level. The model’s diagnostic accuracy was compared with experts’. Five hundred thirteen slides were used to evaluate whether the experts’ diagnostic skills could be improved using the model as an AI-assisted tool. The consistency between experts’ interpretations of microscopic digital images and microscopic examination under eyepiece was assessed to determine whether the collected images adequately represented the slides. The model obtained AUC = 0.9447, 0.9711, and 0.9793 for slide-level diagnosing yeast hyphae, budding yeast, and yeast. Compared with the average performance of experts, the Youden indexes of our model’s best points were improved by 0.0069, 0.0772, 0.0579, and 0.0907 for yeast hyphae, budding yeast, yeast, and VVC. The average accuracy of the experts was improved by 5.98%, 5.20%, 4.82%, and 8.19% using our model as an AI-assisted tool. The consistency rates and Cohen’s kappa coefficients between experts’ interpretations of microscopic digital images and microscopic examination under eyepiece exceeded 93% and 0.83 for the three different morphologic states of yeast. Our model exhibits superior diagnostic accuracy for VVC compared to experts. Experts can significantly improve their own diagnostic accuracies by using our model as an AI-assisted tool. The microscope images collected from each slide effectively represent the slide. IMPORTANCE: A cascaded deep neural network model was developed for slide-level diagnosis of vulvovaginal candidiasis (VVC), demonstrating superior diagnostic accuracy compared to experts. Experts significantly enhanced their diagnostic accuracies by utilizing our model as an AI-assisted tool. Therefore, this model holds potential for clinical application to aid in the diagnosis of VVC.
- Open Access
- 27 November 2024
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 10 (1) , 1-17
Mechanisms of S. agalactiae promoting G. vaginalis biofilm formation leading to recurrence of BV
Previous research has established that the formation of Gardnerella vaginalis (GV) biofilm is one of the primary reasons for bacterial vaginosis (BV) recurrence. This study was the first to explore the impact of Streptococcus agalactiae (group B Streptococcus, GBS) on GV biofilm in a co-culture scenario. The results revealed that GBS could significantly increased the GV biomass in 48-hours dual-species biofilms. The luxS gene of GBS was significantly higher in dual-species biofilm, while knockdown of the luxS gene resulted in a significant decrease in mono- and dual-species biofilms. Meanwhile, in vitro addition of AI-2 (product of luxS gene) substantially increased biofilm biomass. Furthermore, we found that the expression of two genes related to biofilm formation was notably elevated in GV after receiving AI-2 signals. Collectively, these findings suggest that GBS enhances GV biofilm formation via luxS/AI-2 in an in vitro co-culture model, which in turn may promotes recurrence of BV.
- 27 November 2024
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 10 (1) , 1-17
Open AccessMechanisms of S. agalactiae promoting G. vaginalis biofilm formation leading to recurrence of BV
Previous research has established that the formation of Gardnerella vaginalis (GV) biofilm is one of the primary reasons for bacterial vaginosis (BV) recurrence. This study was the first to explore the impact of Streptococcus agalactiae (group B Streptococcus, GBS) on GV biofilm in a co-culture scenario. The results revealed that GBS could significantly increased the GV biomass in 48-hours dual-species biofilms. The luxS gene of GBS was significantly higher in dual-species biofilm, while knockdown of the luxS gene resulted in a significant decrease in mono- and dual-species biofilms. Meanwhile, in vitro addition of AI-2 (product of luxS gene) substantially increased biofilm biomass. Furthermore, we found that the expression of two genes related to biofilm formation was notably elevated in GV after receiving AI-2 signals. Collectively, these findings suggest that GBS enhances GV biofilm formation via luxS/AI-2 in an in vitro co-culture model, which in turn may promotes recurrence of BV.
- Open Access
- 3 April 2024
- Published by Springer Nature in Infection
- Vol. 52 (5) , 1787-1797
Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study
Purpose: To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC). Methods: A double-blind, placebo-controlled, randomized, multicenter phase III study was conducted in symptomatic VVC patients. Patients received (2:1) twice-daily oral ibrexafungerp 300 mg or matching placebo for 1 day. The primary endpoint was clinical cure (vulvovaginal signs and symptoms [VSS] score = 0) at test-of-cure (TOC) on day 11 ± 3. The secondary endpoints included mycological eradication, overall response, and clinical improvement (VSS score ≤ 1) at TOC, and vulvovaginal symptom resolution at follow-up on day 25 ± 4. Results: In total, 360 patients were included in the modified intention-to-treat set (defined as positive Candida cultured and receiving at least one study drug; 239 for ibrexafungerp, 121 for placebo). Compared with placebo, patients receiving ibrexafungerp had a significantly higher proportion of clinical cure (51.0% vs. 25.6%), mycological eradication (55.6% vs. 18.2%), overall response (33.9%, vs. 8.3%) at TOC and complete symptom resolution (74.5% vs. 39.7%, all P < 0.001) at follow-up. Subgroup analysis of clinical cure indicated that patients with C. albicans could benefit from ibrexafungerp over placebo. A similar benefit trend was also observed in those with non-albicans Candida by post-hoc analysis. Further analyses revealed similar efficacy of ibrexafungerp between patients with fluconazole non-susceptible C. albicans and fluconazole susceptible C. albicans regarding clinical cure and mycological eradication. Ibrexafungerp was generally well tolerated. Adverse events were primarily gastrointestinal and were mainly mild in severity. Conclusions: As a first-in-class antifungal agent, ibrexafungerp demonstrated promising efficacy and favorable safety for VVC treatment in Chinese patients. Chinadrugtrials.org.cn registry number: CTR20220918.
- 3 April 2024
- Published by Springer Nature in Infection
- Vol. 52 (5) , 1787-1797
Open AccessEfficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study
Purpose: To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC). Methods: A double-blind, placebo-controlled, randomized, multicenter phase III study was conducted in symptomatic VVC patients. Patients received (2:1) twice-daily oral ibrexafungerp 300 mg or matching placebo for 1 day. The primary endpoint was clinical cure (vulvovaginal signs and symptoms [VSS] score = 0) at test-of-cure (TOC) on day 11 ± 3. The secondary endpoints included mycological eradication, overall response, and clinical improvement (VSS score ≤ 1) at TOC, and vulvovaginal symptom resolution at follow-up on day 25 ± 4. Results: In total, 360 patients were included in the modified intention-to-treat set (defined as positive Candida cultured and receiving at least one study drug; 239 for ibrexafungerp, 121 for placebo). Compared with placebo, patients receiving ibrexafungerp had a significantly higher proportion of clinical cure (51.0% vs. 25.6%), mycological eradication (55.6% vs. 18.2%), overall response (33.9%, vs. 8.3%) at TOC and complete symptom resolution (74.5% vs. 39.7%, all P < 0.001) at follow-up. Subgroup analysis of clinical cure indicated that patients with C. albicans could benefit from ibrexafungerp over placebo. A similar benefit trend was also observed in those with non-albicans Candida by post-hoc analysis. Further analyses revealed similar efficacy of ibrexafungerp between patients with fluconazole non-susceptible C. albicans and fluconazole susceptible C. albicans regarding clinical cure and mycological eradication. Ibrexafungerp was generally well tolerated. Adverse events were primarily gastrointestinal and were mainly mild in severity. Conclusions: As a first-in-class antifungal agent, ibrexafungerp demonstrated promising efficacy and favorable safety for VVC treatment in Chinese patients. Chinadrugtrials.org.cn registry number: CTR20220918.
- Open Access
- 10 January 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (1) , e0077823
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial
Vulvovaginal candidiasis (VVC) is a common condition among women. Fluconazole remains the dominant treatment option for VVC. Oteseconazole is a highly selective inhibitor of fungal CYP51. This randomized, double-blinded, phase 3 trial was conducted to evaluate the efficacy and safety of oteseconazole compared with fluconazole in treating severe VVC. Female subjects presenting with vulvovaginal signs and symptoms score of ≥7 and positive Candida infection determined by potassium hydroxide test or Gram staining were randomly assigned to receive oteseconazole (600 mg on D1 and 450 mg on D2) or fluconazole (150 mg on D1 and D4) in a 1:1 ratio. The primary endpoint was the proportion of subjects achieving therapeutic cure [defined as achieving both clinical cure (absence of signs and symptoms of VVC) and mycological cure (negative culture of Candida species)] at D28. A total of 322 subjects were randomized and 321 subjects were treated. At D28, a statistically significantly higher proportion of subjects achieved therapeutic cure in the oteseconazole group than in the fluconazole group (66.88% vs 45.91%; P = 0.0002). Oteseconazole treatment resulted in an increased proportion of subjects achieving mycological cure (82.50% vs 59.12%; P < 0.0001) and clinical cure (71.25% vs 55.97%; P = 0.0046) compared with fluconazole. The incidence of treatment-emergent adverse events was similar between the two groups. No subjects discontinued study treatment or withdrew study due to adverse events. Oteseconazole showed statistically significant and clinically meaningful superiority over fluconazole for the treatment of severe VVC and was generally tolerated.
- 10 January 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (1) , e0077823
Open AccessOteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial
Vulvovaginal candidiasis (VVC) is a common condition among women. Fluconazole remains the dominant treatment option for VVC. Oteseconazole is a highly selective inhibitor of fungal CYP51. This randomized, double-blinded, phase 3 trial was conducted to evaluate the efficacy and safety of oteseconazole compared with fluconazole in treating severe VVC. Female subjects presenting with vulvovaginal signs and symptoms score of ≥7 and positive Candida infection determined by potassium hydroxide test or Gram staining were randomly assigned to receive oteseconazole (600 mg on D1 and 450 mg on D2) or fluconazole (150 mg on D1 and D4) in a 1:1 ratio. The primary endpoint was the proportion of subjects achieving therapeutic cure [defined as achieving both clinical cure (absence of signs and symptoms of VVC) and mycological cure (negative culture of Candida species)] at D28. A total of 322 subjects were randomized and 321 subjects were treated. At D28, a statistically significantly higher proportion of subjects achieved therapeutic cure in the oteseconazole group than in the fluconazole group (66.88% vs 45.91%; P = 0.0002). Oteseconazole treatment resulted in an increased proportion of subjects achieving mycological cure (82.50% vs 59.12%; P < 0.0001) and clinical cure (71.25% vs 55.97%; P = 0.0046) compared with fluconazole. The incidence of treatment-emergent adverse events was similar between the two groups. No subjects discontinued study treatment or withdrew study due to adverse events. Oteseconazole showed statistically significant and clinically meaningful superiority over fluconazole for the treatment of severe VVC and was generally tolerated.
- Open Access
- 2 December 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (12) , 1159
Loop-Mediated Isothermal Amplification (LAMP): Potential Point-of-Care Testing for Vulvovaginal Candidiasis
Purpose: The aim of this study is to establish a loop-mediated isothermal amplification (LAMP) method for the rapid detection of vulvovaginal candidiasis (VVC). Methods: We developed and validated a loop-mediated isothermal amplification (LAMP) method for detecting the most common Candida species associated with VVC, including C. albicans, N. glabratus, C. tropicalis, and C. parapsilosis. We evaluated the specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and Kappa value of the LAMP method to detect different Candida species, using the conventional culture method and internal transcribed spacer (ITS) sequencing as gold standards and smear Gram staining and real-time Rolymerase Chain Reaction (PCR) as controls. Results: A total of 202 cases were enrolled, of which 88 were VVC-positive and 114 were negative. Among the 88 positive patients, the fungal culture and ITS sequencing results showed that 67 cases (76.14%) were associated with C. albicans, 13 (14.77%) with N. glabratus, 5 (5.68%) with C. tropicalis, and 3 (3.41%) with other species. Regarding the overall detection rate, the LAMP method presented sensitivity, specificity, PPV, NPV, and Kappa values of 90.91%, 100%, 100%, 93.4%, and 0.919, respectively. Moreover, the LAMP had a specificity of 100% for C. albicans, N. glabratus, and C. tropicalis, with a sensitivity of 94.03%, 100%, and 80%, respectively. Moreover, the microscopy evaluation had the highest sensitivity, while the real-time PCR was less specific for C. albicans than LAMP. In addition, CHROMagar Candida was inferior to LAMP in detecting non-albicans Candida (NAC) species. Conclusions: Based on the cost-effective, rapid, and inexpensive characteristics of LAMP, coupled with the high sensitivity and specificity of our VVC-associated Candida detection method, we provided a possibility for the point-of-care testing (POCT) of VVC, especially in developing countries and some laboratories with limited resources.
- 2 December 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (12) , 1159
Open AccessLoop-Mediated Isothermal Amplification (LAMP): Potential Point-of-Care Testing for Vulvovaginal Candidiasis
Purpose: The aim of this study is to establish a loop-mediated isothermal amplification (LAMP) method for the rapid detection of vulvovaginal candidiasis (VVC). Methods: We developed and validated a loop-mediated isothermal amplification (LAMP) method for detecting the most common Candida species associated with VVC, including C. albicans, N. glabratus, C. tropicalis, and C. parapsilosis. We evaluated the specificity, sensitivity, positive predictive value (PPV), negative predictive value (NPV), and Kappa value of the LAMP method to detect different Candida species, using the conventional culture method and internal transcribed spacer (ITS) sequencing as gold standards and smear Gram staining and real-time Rolymerase Chain Reaction (PCR) as controls. Results: A total of 202 cases were enrolled, of which 88 were VVC-positive and 114 were negative. Among the 88 positive patients, the fungal culture and ITS sequencing results showed that 67 cases (76.14%) were associated with C. albicans, 13 (14.77%) with N. glabratus, 5 (5.68%) with C. tropicalis, and 3 (3.41%) with other species. Regarding the overall detection rate, the LAMP method presented sensitivity, specificity, PPV, NPV, and Kappa values of 90.91%, 100%, 100%, 93.4%, and 0.919, respectively. Moreover, the LAMP had a specificity of 100% for C. albicans, N. glabratus, and C. tropicalis, with a sensitivity of 94.03%, 100%, and 80%, respectively. Moreover, the microscopy evaluation had the highest sensitivity, while the real-time PCR was less specific for C. albicans than LAMP. In addition, CHROMagar Candida was inferior to LAMP in detecting non-albicans Candida (NAC) species. Conclusions: Based on the cost-effective, rapid, and inexpensive characteristics of LAMP, coupled with the high sensitivity and specificity of our VVC-associated Candida detection method, we provided a possibility for the point-of-care testing (POCT) of VVC, especially in developing countries and some laboratories with limited resources.
- Open Access
- 22 May 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13
Analysis of the microbiota composition in the genital tract of infertile patients with chronic endometritis or endometrial polyps
Background: The previous researches show that infertile patients have a higher incidence of endometritis and endometrial polyps, and the occurrence of these two diseases is related to changes in the microbiota of the genital tract. We aim to determine the composition and changing characteristics of the microbiota in the genital tract (especially the endometrium) of infertile patients with chronic endometritis or endometrial polyps, and find the correlation between it and the occurrence of diseases.Methods: This is a prospective study. We collected genital tract biopsy samples from 134 asymptomatic infertile patients receiving assisted reproductive therapy before embryo transfer. Through pathological examination and 16S ribosomal RNA(16S rRNA) sequencing, we determined the distribution of chronic endometritis and endometrial polyps in these patients, as well as their distribution of reproductive tract microorganisms.Results: Compared with the normal control group, the microbial group of reproductive tract in patients with chronic endometritis and endometrial polyps is changed, and there are significant species differences and relative abundance differences in the vagina, cervix and uterine cavity. Lactobacillus, the dominant flora of female genital tract, showed a change in abundance in patients with endometrial diseases. Endometrial microbiota composed of Staphylococcus, Gardnerella, Atopobium, Streptococcus, Peptostreptococcus, Chlamydia, Fusobacterium, Acinetobacter, etc. are related to chronic endometritis and endometrial polyps.Conclusion: The results showed that, compared with the normal control group, the endometrial microbiota of infertile patients with chronic endometritis or endometrial polyps did have significant changes in the relative abundance distribution of species, suggesting that changes in local microecology may be an important factor in the occurrence of disease, or even adverse pregnancy outcomes. The further study of endometrial microecology may provide a new opportunity to further improve the diagnosis and treatment strategy of chronic endometritis.
- 22 May 2023
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 13
Open AccessAnalysis of the microbiota composition in the genital tract of infertile patients with chronic endometritis or endometrial polyps
Background: The previous researches show that infertile patients have a higher incidence of endometritis and endometrial polyps, and the occurrence of these two diseases is related to changes in the microbiota of the genital tract. We aim to determine the composition and changing characteristics of the microbiota in the genital tract (especially the endometrium) of infertile patients with chronic endometritis or endometrial polyps, and find the correlation between it and the occurrence of diseases.Methods: This is a prospective study. We collected genital tract biopsy samples from 134 asymptomatic infertile patients receiving assisted reproductive therapy before embryo transfer. Through pathological examination and 16S ribosomal RNA(16S rRNA) sequencing, we determined the distribution of chronic endometritis and endometrial polyps in these patients, as well as their distribution of reproductive tract microorganisms.Results: Compared with the normal control group, the microbial group of reproductive tract in patients with chronic endometritis and endometrial polyps is changed, and there are significant species differences and relative abundance differences in the vagina, cervix and uterine cavity. Lactobacillus, the dominant flora of female genital tract, showed a change in abundance in patients with endometrial diseases. Endometrial microbiota composed of Staphylococcus, Gardnerella, Atopobium, Streptococcus, Peptostreptococcus, Chlamydia, Fusobacterium, Acinetobacter, etc. are related to chronic endometritis and endometrial polyps.Conclusion: The results showed that, compared with the normal control group, the endometrial microbiota of infertile patients with chronic endometritis or endometrial polyps did have significant changes in the relative abundance distribution of species, suggesting that changes in local microecology may be an important factor in the occurrence of disease, or even adverse pregnancy outcomes. The further study of endometrial microecology may provide a new opportunity to further improve the diagnosis and treatment strategy of chronic endometritis.
- Open Access
- 14 March 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-13
Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols
Endometrial carcinoma (EC) is one of the most common gynecological malignancies in China and globally, accounting for the fourth-prevalent cancer in women. Although numerous studies have confirmed prognostic value of The Cancer Genome Atlas (TCGA) molecular subgroups, it is unclear how they are combined with histological features. The main objective of this study was to compare ProMisE and TCGA classification for the rapid and accurate prediction of prognosis within EC patients, together with the provision of a revised strategy for individualized diagnosis and treatment of patients. Within this study, 70 patients with EC from Beijing Tsinghua Changgeng Hospital (affiliated to Tsinghua University) were retrospectively examined between July 2015 and December 2021. Samples were processed for determination of clinical markers, together with ProMisE and TCGA classification. Comparative analysis across four TCGA types (POLE, Low-CN, High-CN, and MSI-H) and age, was statistically significant (χ²= 7.000, p = 0.029). There was no significant difference observed among the four TCGA types and FIGO stage, vascular invasion and depth of invasion, or lymph node metastasis and tumor area. There was no significant association between the expression of Vimentin, Ki-67, PTEN, MSH2, PAX-8, β-catenin, CD10, ER, PR, P16, MLH1, and PMS2 with the four TCGA types. In addition, p63 expression (χ²= 11.09, p = 0.029) and p53 expression (χ²= 11.585, p = 0.005) were statistically significant. Numerous models demonstrated that patients with POLE mutations and low-CN had higher progression free survival (PFS) and overall survival (OS), whereas those with high-CN had lowest values. The log-rank test revealed that the survival rate of PR-positive and ER-positive patients was significantly higher (p < 0.001). Overall, these results can be of additional benefit for clinical applications, in comparison to the ProMisE classification method. In addition, PR, ER, vascular infiltration, hyperlipidemia and atherosclerosis were found to be the key factors affecting EC prognosis.
- 14 March 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-13
Open AccessClinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols
Endometrial carcinoma (EC) is one of the most common gynecological malignancies in China and globally, accounting for the fourth-prevalent cancer in women. Although numerous studies have confirmed prognostic value of The Cancer Genome Atlas (TCGA) molecular subgroups, it is unclear how they are combined with histological features. The main objective of this study was to compare ProMisE and TCGA classification for the rapid and accurate prediction of prognosis within EC patients, together with the provision of a revised strategy for individualized diagnosis and treatment of patients. Within this study, 70 patients with EC from Beijing Tsinghua Changgeng Hospital (affiliated to Tsinghua University) were retrospectively examined between July 2015 and December 2021. Samples were processed for determination of clinical markers, together with ProMisE and TCGA classification. Comparative analysis across four TCGA types (POLE, Low-CN, High-CN, and MSI-H) and age, was statistically significant (χ²= 7.000, p = 0.029). There was no significant difference observed among the four TCGA types and FIGO stage, vascular invasion and depth of invasion, or lymph node metastasis and tumor area. There was no significant association between the expression of Vimentin, Ki-67, PTEN, MSH2, PAX-8, β-catenin, CD10, ER, PR, P16, MLH1, and PMS2 with the four TCGA types. In addition, p63 expression (χ²= 11.09, p = 0.029) and p53 expression (χ²= 11.585, p = 0.005) were statistically significant. Numerous models demonstrated that patients with POLE mutations and low-CN had higher progression free survival (PFS) and overall survival (OS), whereas those with high-CN had lowest values. The log-rank test revealed that the survival rate of PR-positive and ER-positive patients was significantly higher (p < 0.001). Overall, these results can be of additional benefit for clinical applications, in comparison to the ProMisE classification method. In addition, PR, ER, vascular infiltration, hyperlipidemia and atherosclerosis were found to be the key factors affecting EC prognosis.
- Open Access
- 20 December 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 1069254
The role of upper and lower genital tract microbiota alterations in term chorionamnionitis: A prospective study
Objective: This study aimed to compare the dynamics of lower and upper genital tract microbiota in normal term pregnancy, histological chorioamnionitis (HCA), and clinical chorioamnionitis (CCA) patients to provide a reference for the diagnosis and treatment of chorioamnionitis (CAM) patients.Methods: We prospectively collected vaginal and cervical secretions, as well as placenta tissues, fetal membranes, and amniotic fluid from normal-term pregnant women, HCA and CCA patients. Then, we performed genomic DNA extraction and PCR amplification for all samples. The eligible samples were analyzed by 16S ribosomal RNA (16S rRNA) sequencing. Additionally, all placenta tissues were histopathologically examined, and neonatal pharyngeal swabs and placenta tissues from the HCA and CCA groups were subjected to microbial culture.Results: A total of 85 term pregnant women were enrolled in this study, including 34 in the normal group (N), 37 in the HCA group, and 14 in the CCA group. A total of 171 qualified samples were analyzed by 16S rRNA sequencing. The results suggested that the cervical microbiota was highly similar to the vaginal microbiota in normal term parturients, with Lactobacillus as the dominant bacterium. Moreover, there was no difference in the alpha and beta diversity of vaginal microbiota between the N, HCA, and CCA groups at the genus level. Besides, no significant differences were detected in cervical microbiome among the three groups. Regarding intrauterine microorganisms, the N and HCA groups had similar microbial composition but were different from the CCA group. No microbe was detected in the placental tissue of normal term parturients, while some microorganisms were found in the intrauterine amniotic fluid and fetal membrane samples. Regardless of cultivation or 16S rRNA sequencing, an extremely low microbial positive rate was detected in HCA and CCA intrauterine samples. Compared to the normal group, Lactobacillus was significantly reduced in the CCA group intrauterine, and Ureaplasma and Enterococcus increased with no statistically significant.Conclusion: The N, HCA and CCA groups had similar composition of vaginal and cervical microflora. Some normal-term pregnant women can harbor non-pathogenic microbiota in the uterine cavity. Sterile inflammation is more frequent than microbial-associated inflammation in term HCA and CCA parturients.
- 20 December 2022
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 13, 1069254
Open AccessThe role of upper and lower genital tract microbiota alterations in term chorionamnionitis: A prospective study
Objective: This study aimed to compare the dynamics of lower and upper genital tract microbiota in normal term pregnancy, histological chorioamnionitis (HCA), and clinical chorioamnionitis (CCA) patients to provide a reference for the diagnosis and treatment of chorioamnionitis (CAM) patients.Methods: We prospectively collected vaginal and cervical secretions, as well as placenta tissues, fetal membranes, and amniotic fluid from normal-term pregnant women, HCA and CCA patients. Then, we performed genomic DNA extraction and PCR amplification for all samples. The eligible samples were analyzed by 16S ribosomal RNA (16S rRNA) sequencing. Additionally, all placenta tissues were histopathologically examined, and neonatal pharyngeal swabs and placenta tissues from the HCA and CCA groups were subjected to microbial culture.Results: A total of 85 term pregnant women were enrolled in this study, including 34 in the normal group (N), 37 in the HCA group, and 14 in the CCA group. A total of 171 qualified samples were analyzed by 16S rRNA sequencing. The results suggested that the cervical microbiota was highly similar to the vaginal microbiota in normal term parturients, with Lactobacillus as the dominant bacterium. Moreover, there was no difference in the alpha and beta diversity of vaginal microbiota between the N, HCA, and CCA groups at the genus level. Besides, no significant differences were detected in cervical microbiome among the three groups. Regarding intrauterine microorganisms, the N and HCA groups had similar microbial composition but were different from the CCA group. No microbe was detected in the placental tissue of normal term parturients, while some microorganisms were found in the intrauterine amniotic fluid and fetal membrane samples. Regardless of cultivation or 16S rRNA sequencing, an extremely low microbial positive rate was detected in HCA and CCA intrauterine samples. Compared to the normal group, Lactobacillus was significantly reduced in the CCA group intrauterine, and Ureaplasma and Enterococcus increased with no statistically significant.Conclusion: The N, HCA and CCA groups had similar composition of vaginal and cervical microflora. Some normal-term pregnant women can harbor non-pathogenic microbiota in the uterine cavity. Sterile inflammation is more frequent than microbial-associated inflammation in term HCA and CCA parturients.
- 19 August 2022
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 134 (7) , 659-667
Natural progress history of asymptomatic bacterial vaginosis in Chinese Han women and associated risk factors
Asymptomatic bacterial vaginosis (aBV) is prevalent in the general population, while a previous study only investigated the natural history of aBV in women at high-risk. This stage study was to inv...
- 19 August 2022
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 134 (7) , 659-667
Natural progress history of asymptomatic bacterial vaginosis in Chinese Han women and associated risk factors
Asymptomatic bacterial vaginosis (aBV) is prevalent in the general population, while a previous study only investigated the natural history of aBV in women at high-risk. This stage study was to inv...